Cobra Biologics, an international CDMO, has successfully produced and delivered the first DNA plasmid required to produce CombiGene’s gene therapy drug candidate CG01, for the treatment of drug-resistant focal epilepsy.   For the vital compounds of CG01, Cobra Biologics has finalized production and delivery of the first of three key plasmids, enabling the downstream processes to be initiated. In addition to these plasmids, a specific type of cell, which Cobra is also producing, acting as the ‘...